CD38 and Miyoshi myopathy: Besides the induction of effector-mediated MM cell lysis in a CD38-dependent manner, both daratumumab and isatuximab eliminate high CD38-expressing immune inhibitory cell subsets (i.e., Treg, Breg) in MM patients, a supplementary mechanism to increase immune effector cell number and function [11,12,13].